PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2368
https://www.valueinhealthjournal.com/article/S1098-3015(19)34746-1/fulltext
Title :
PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34746-1&doi=10.1016/j.jval.2019.09.2368
First page :
Section Title :
Open access? :
No
Section Order :
12064